Imaging discovery could accelerate drug development
The organic fluorophore’s super-photostability enables tracking of previously undetectable biological processes hindered with traditional fluorescent dyes.
List view / Grid view
The organic fluorophore’s super-photostability enables tracking of previously undetectable biological processes hindered with traditional fluorescent dyes.
The cleaner method could significantly lower production costs and reduce carbon dioxide emissions resulting from ethylene oxide manufacturing.
The agency’s decision means eligible adult patients in the UK are set to access the combination immunotherapy as a new treatment option for acute lymphoblastic leukaemia (ALL).
Proposed US tariffs on pharmaceutical imports could disrupt global supply chains, drive up production costs, and exacerbate drug shortages. How will the industry respond?
Ahead of the Critical Medicines Act anticipated in 2025, Teva’s report offers policy recommendations to mitigate the economic pressures risking generic medicine availability in Europe.
The research highlights potential for the technology to advance development of pharmaceutically relevant peptide amides as therapies.
The paper highlights a new analytical method that provides potential for sustainable use of nanomaterials and unique benefits compared to other spectrofluorimetric techniques.
A major overhaul of the UK’s Apprenticeship Levy promises to deliver greater flexibility for pharmaceutical workforce training, helping to address critical skills shortages.
As a significant water consumer to enable production of high-quality medicines, this demand brings both challenges and opportunities for the pharmaceutical industry up to 2033, research suggests.
Here, Dr Jinpeng Li at WuXi AppTec reveals the analytical challenges that are hindering advancement of oligonucleotide therapeutics, medicines which have demonstrated clinical promise in the gene therapy space, and discusses promising analytical innovations.
The directive could lead to nearly €1 billion in additional costs for pharmaceutical companies in Finland alone, states Orion Corporation.
The authorisation provides a new disease modifying treatment option for European patients with the progressive condition.
The potentially multi-billion-dollar deal strengths Novartis’ late-stage pipeline for cardiovascular therapies, signalling advancement of novel treatments for heart disease.
Under growing global competition, this development highlights potential challenges for the UK to uphold large-scale pharmaceutical investments.
New data suggests that once-weekly prophylaxis bispecific antibody treatment could provide an efficient and convenient option for young patients with haemophilia A.